Busulfan is currently used as a main component in the conditioning regimen prior to allogeneic stem cell transplantation (SCT). Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. Busulfan is metabolized mainly through glutathione (GSH). During highdose therapy, busulfan may deplete hepatocellular levels of GSH. As part of the conditioning therapy, busulfan is usually followed by high doses of cyclophosphamide. The activation of cyclophosphamide yields a cytotoxic metabolite, 4-hydroxy cyclophosphamide, which is highly reactive and detoxified through GSH. According to recent studies using cell lines and animal models N-acetyl-lcysteine (NAC), a GSH precursor, does not hamper the myeloablative effect of busulfan during conditioning. In the present study, we administered NAC during conditioning to 10 patients at risk of VOD due to pretransplant liver disorders or elevated liver enzymes. No side effects related to the NAC infusions were observed and busulfan concentrations were not affected. All patients became pancytopenic and engrafted with 100% donor cells. None of the patients developed VOD or liver failure. Increased liver enzymes during conditioning decreased or normalized in all patients. We suggest that NAC therapy is safe and does not impair the myeloablative effect of busulfan during conditioning prior to SCT.
Busulfan is an alkylating agent that mainly targets hematopoietic stem cells and early progenitors. 1, 2 It is currently used in high doses as an alternative to irradiation therapy in conditioning regimen prior to stem cell transplantation (SCT). [3] [4] [5] Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. [5] [6] [7] [8] [9] Apart from acute GVHD and infections, VOD is one of the common early complications with a potential fatal outcome following SCT. 5, 6 Hepatic VOD is a clinical syndrome consisting of jaundice, ascites and/or unexplained weight gain, and hepatomegaly and/or upper-quadrant abdominal pain, as defined by McDonald et al 10 and Jones et al. 11 Endothelial cell damage, due to toxicity of pretransplant conditioning chemotherapy and/or irradiation, leading to activation of clotting factors, is believed to be an early event. 12, 13 Low constitutive levels of glutathione (GSH), the most important intracellular antioxidant, in centrilobular hepatocytes, together with further glutathione exhaustion by cytotoxic drugs or radiation may contribute to the development of VOD.
14 Involvement of GSH in the metabolism of busulfan has been studied in animal models and in man. [15] [16] [17] Several investigations have confirmed that busulfan is metabolized in the liver through conjugation with GSH catalyzed by glutathione S-transferase (GST). The reaction is catalyzed in human liver mainly by GST-A1-1. 18, 19 Treatment with busulfan depleted GSH by 60% in murine hepatocytes in vivo and by 50% in vitro. 20 In the same study, modulation of the cellular levels of GSH changed hepatocyte cytotoxity of busulfan: cells depleted of GSH were more sensitive and cells with increased GSH less sensitive to the toxic effect. Precursors of GSH, such as N-acetyl-l-cysteine (NAC), increase the cellular content of GSH. 21 NAC is currently used intravenously to treat hepatotoxicity due to acetaminophen. 22 Recently, a case report of three patients with VOD successfully treated with NAC was published. 23 NAC has few and mild side effects and is therefore a candidate drug for VOD prophylaxis presuming that it does not interfere with the myeloablative effect of the conditioning regimen. Hematopoietic stem cells do not express GSTA1, but they do express other GST isoforms. 24, 25 However, these GST isoforms have lower activity in the combination of busulfan with GSH. 18 In a recent study by Hassan et al, 26 the effect of modulation of the cellular content of GSH on busulfan cytotoxicity in hematopoietic progenitors was studied in vitro and in vivo. By using three parallel systems, normal human CD34+ hematopoietic progenitor cells and a myeloid cell line in vitro as well as a murine model for the in vivo studies, it was shown that modulation of GSH content in hematopoietic cells does not counteract the hematotoxic effect of the drug.
In the current study, we included 10 patients at high risk of VOD. They were given prophylactic treatment with NAC during pretransplant conditioning. The aim was to analyze whether NAC interacted with busulfan during conditioning prior to SCT in patients at high risk of liver toxicity.
Patients and methods

Patients
A total of 10 patients, who underwent allogeneic SCT between October 2000 and May 2002, were included. Six patients were transplanted with stem cells from matched unrelated donors, three with stem cells from HLA identical sibling donors and one with cord blood. Table 1 summarizes the patient characteristics. The criteria for inclusion were alanine aminotransferase (ALT) 41.4 mkat/l and/ or total bilirubin 426 mmol/l as signs of liver damage. As described below, the initial patients received NAC only on the resting day between busulfan and cyclophosphamide. Patient 5 had been included on the basis of elevated ALT before starting conditioning. However, when NAC was administered, at the end of busulfan treatment, the ALT had normalized. Patient 2 received a single dose of NAC during conditioning due to the presence of excessive busulfan concentrations. Despite the fact that this case does not match the regular inclusion criteria, it might add important data about the use of NAC during busulfan treatment and it is therefore included. In two of the patients (1 and 10), a previous liver biopsy had established a diagnosis of hemochromatosis. All patients had tested negative for viral hepatitis B and C during pretransplantation evaluation.
Treatment with busulfan and NAC
The conditioning regimen was determined depending on age and diagnosis according to the general principles and procedures at our center. Six patients (patients 1, 2, 4, 5, 7, 8) were conditioned with oral busulfan given for 4 days and cyclophosphamide 60 mg/kg/day for 2 days. The initial busulfan dose was administered as 4 mg/kg/day. Busulfan was given twice daily. In cases of high busulfan serum concentrations, the dose was reduced during conditioning, as described below. Pediatric patients (patients 3 and 6) received liposomal busulfan 27 divided into eight doses for 4 days (total dose 500 mg/m 2 ) and cyclophosphamide as described for the previous group. Patient 10 received reduced conditioning with busulfan, 4 mg/kg/day, given for 2 days, and fludarabine 30 mg/m 2 /day during 6 days. Patient 9 received cyclophosphamide 50 mg/kg/day for 4 days. We previously used NAC at our center during the post transplantation period with almost no side effects. NAC was given twice daily 50 mg/kg. The first patients treated during conditioning received NAC exclusively on the resting day between busulfan and cyclophosphamide and the dose was divided as described above. Based on our initial experience and our animal data, we were also able to start NAC treatment between the busulfan doses. The NAC dosage was modified to a single daily dose of 100 mg/ kg, in order to conveniently keep the accurate time interval between busulfan doses. Since this treatment was equally well tolerated, we also started administrating NAC once daily post chemotherapy. This schedule was given to all ensuing patients. Treatment with NAC was thus generally given once daily as a 3-h infusion, 100 mg per kg body weight starting 6-h after the previous busulfan dose and ending 3 h before the subsequent dose. The number of NAC doses given during and after busulfan treatment among the patients is described in Table 2 . Treatment with NAC was stopped at least 12 h before cyclophosphamide treatment. When restarted, NAC was administered no earlier than 12 h after the end of the cyclophosphamide infusion. The treatment was continued until elevated liver transaminases normalized or, if transaminases were normal at initiation of therapy, until conditioning was complete.
Busulfan levels determination
Busulfan was determined using gas chromatography with an electron capture detector as described previously. 28 Briefly, internal standard (1,5-bi(methanesulfonoxy) pentane was added to 0.5 ml plasma. Busulfan and the internal standard were converted to 1,4-diiodobutane and 1,5-diiodopentane, respectively. The area under plasma concentration time curves (AUCs) for each patient were measured after the oral administration as described previously using a limited sampling model (based on three time points) 1, 3 and 6 h, 29, 30 
Patient care
Tissue typing, conditioning, GVHD prophylaxis and infection prophylaxis have previously been published in detail. In short, patients were treated in reverse isolation. Immunosuppression consisted of four doses of methotrexate combined with cyclosporine and antithymocyte globuline (Thymoglobuline R, IMTIX-Sangstat, Lyon, France), which was given to recipients of unrelated stem cells. 31 
Results
The course of transplantation: liver function, VOD, neutropenia, chimerism, and outcome
The aim of this study was not to determine the therapeutic effect of NAC and the study design does not allow any 100 mg/kg once daily 9 5+6 Given as a 3-h infusion starting 4 h before and 6 h after each cyclophosphamide dose 100 mg/kg twice daily on day À3 and À2, otherwise 100 mg/kg once daily 10 7+12 Given between busulfan and between fludarabine doses 100 mg/kg conclusions concerning the putative benefit from administering this drug to patients with liver toxicity. It can, however be noted that in all but one patient the liver enzymes normalized completely (Table 3) and none of the patients developed VOD or fatal liver toxicity. Leukopenia developed in all patients ( Table 4 ). The leukopenia (WBC o0.5 Â 10 9 /l) lasted a median of 13 days (range 5-24 days). Chimerism data at 3 months after SCT were available for five patients showing 100% donor origin of hematopoietic cells (CD3+, Cd19+, CD45+) in peripheral blood (Table 4) . The majority of patients experienced acute GVHD (Table 4) . One recurrence of leukemia was reported 15 months after transplantation. One patient died from acute GVHD on day 55 after SCT. The other patients have remained disease free and are alive at a median follow-up of 6 months (range 1-20 months).
Busulfan serum concentrations
Busulfan AUCs were compared before and after the administration of NAC (Table 5 ). Serum busulfan concentrations were not affected by NAC treatment. However, high concentrations of busulfan were found in patients 2, 4 and 8 before starting NAC therapy. The AUCs after the first dose of busulfan were 20 526, 15 527 and 16 122 ng/ml h for the three patients, respectively. The doses were reduced by 35, 15 and 30%, respectively, and the mean values of the AUCs during doses 4-8 were 11 430, 10 551 and 12 122 ng/ml h, respectively. The AUCs of busuphan for these patients were not affected by NAC therapy, when they were corrected for 2 mg/kg ( Table 5 ). The AUC aimed for were within the range (4000-5000 ng/ml h) after a dose of 1 mg/kg or 8000-10 000 ng/ml h after a dose of 2 mg/kg. These values are in agreement with those reported by Grochow et al. 6 
Discussion
The most important finding in this study is that NAC was well tolerated, did not alter the myeloablative effect of busulfan and most probably prevented the occurrence of VOD in a group of patients at a high risk and/or with signs of liver toxicity at the start of conditioning. This study was not designed to determine any therapeutic effect of NAC since the effects of NAC are well documented in several studies in patients with liver toxicity after paracetamol overdose, 32 septic shock 33 and in preterm new born infants. 34 In the present paper we treated 10 patients at high risk of VOD with NAC. NAC was given between repeated busulfan or cyclophosphamide doses and/or between busulfan and cyclophosphamide administration. No side effects related to the NAC infusions were observed and busulfan serum concentrations were not affected. Furthermore, no significant differences in duration of neutropenia, chimerism data or frequency of acute GVHD were found as compared with previous experience. 31, 35 None of the patients developed VOD or liver failure. The liver enzymes which increased during conditioning decreased or normalized in all patients. Busulfan is metabolized mainly through GSH. During high-dose treatment, busulfan may deplete cellular levels of GSH in the liver. In conditioning regimens, busulfan is usually followed by a high dose of cyclophosphamide, a prodrug that requires activation through cytochrome P-450 enzymes. The activation of Table 4 Course of transplantation and patient outcome 33 have shown that NAC administration has resulted in an increase in the absolute liver blood flow index, which may have caused an enhancement in nutritive blood flow.
In the present study, we hypothesized that the administration of NAC, a precursor of GSH, to patients at risk of VOD due to pre transplant liver disorders or elevated liver enzymes may reduce the risk of VOD. A recent study using cell lines and animal models has indicated that NAC might be a safe and effective prophylactic therapy during conditioning without hampering the myeloablative effect of busulfan. 26 It was also reported 32 that NAC kinetics were not affected by the liver status in severe paracetamol poisoning and the half-life was about 5.7 h, which is in agreement with subjects with normal liver function. Moreover, Ahola et al 34 have reported a prolonged half-life (11 hours) in pre-term newborn infants, which was probably due to the low hepatic acetylation in this group of patients. This study showed that the elimination of NAC took as long as 6 h and that it was not impaired by the liver status, which is probably similar in patients receiving busulfan. We observed no differences in busulfan kinetics between the first and last doses, as is shown in Table 5 , despite the fact that NAC half-life is quite long 32 and sufficient NAC will be present when busulfan is administred, indicating no influence of NAC on busulfan kinetics. The findings of the present study, in combination with data obtained from animal and in vitro models, provide evidence that NAC does not interfere with the myeloablative effect of a busulfan containing conditioning regimen in any significant way. 26 Only one leukemia relapse has occurred among our patients to date. Thus, to date there is no indication of an increased risk at relapse. However, the follow-up time is short and many more patients need to be included before a definitive conclusion can be made. NAC administration may be an effective prophylactic treatment against VOD and hepatic toxicity during conditioning chemotherapy. The present report is not a prospective randomized study and the number of patients is limited. A randomized study among patients at risk for VOD is ongoing, to validate our findings. In conclusion, NAC therapy can be used safely during conditioning prior to SCT.
